Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thero2-01S22 add-on to anti-HER2 therapy in metastatic breast cancer
NCT05698186Phase 3Not yet recruiting
- Sponsor
- Institut de cancérologie Strasbourg Europe
- Start
- May 2023
- Primary completion
- May 2027
01
Overview
A Phase 3 trial of thero2-01s22 in HER2-positive metastatic breast cancer, sponsored by Institut de cancérologie Strasbourg Europe. Planned start May 2023; status: not yet recruiting.
02
Drugs
thero2-01s22
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT05698186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05698186.